Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Provided By GlobeNewswire
Last update: Jul 15, 2024
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline
3.89
-0.14 (-3.47%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
